/GANX

GANX Stock - Gain Therapeutics, Inc.

Q: What is the analyst price target for GANX?

Analyst price target information is not currently available for GANX.

Q: What is GANX's market cap?

Market capitalization information is not currently available for GANX.

Healthcare|Biotechnology|NASDAQ

$2.88+27.78%

+$0.63 (+27.78%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+189.7%upside

Target: $8.33

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GANX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.06

52W High$4.34

52W Low$1.41

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	$55,180	$132,640	$133,928	$28,881
Gross Profit	N/A	$55,180	$-8,110,440	$-7,030,301	$28,881
Gross Margin	N/A	100.0%	-6114.6%	-5249.3%	100.0%
Operating Income	$-20,350,592	$-22,253,133	$-17,777,045	$-13,826,173	$-3,479,449
Net Income	$-20,411,191	$-22,267,520	$-17,590,738	$-13,890,606	$-3,577,682
Net Margin	N/A	-40354.3%	-13262.0%	-10371.7%	-12387.7%
EPS	$-0.89	$-1.71	$-1.48	$-1.37	$-0.30

Company Overview

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

3 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 213.0% Upside

Now

Low

Average

$12

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
March 7th 2025	Scotiabank	Initiation	Sector Outperform	$12
December 6th 2024	ROTH MKM	Initiation	Buy	$7
August 14th 2024	Oppenheimer	Resumed	Outperform	$8

Earnings History & Surprises

GANX

Beat Rate

47%

Last 19 quarters

Avg Surprise

-6.0%

EPS vs Estimate

Beats / Misses

9/8

2 met exactly

Latest EPS

$-0.15

Q4 2025

EPS Surprise History

Q1 24

+9.4%

$-0.29vs$-0.32

Q2 24

+26.7%

$-0.22vs$-0.30

Q3 24

-35.5%

$-0.42vs$-0.31

Q4 24

+26.1%

$-0.17vs$-0.23

Q1 25

+38.9%

$-0.11vs$-0.18

Q2 25

0.0%

$-0.16vs$-0.16

Q3 25

-11.8%

$-0.19vs$-0.17

Q4 25

0.0%

$-0.15vs$-0.15

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 26, 2026	$-0.14	—	—	—
Q4 2025	Nov 12, 2025	$-0.15	$-0.15	0.0%	= MET
Q3 2025	Aug 12, 2025	$-0.17	$-0.19	-11.8%	✗ MISS
Q2 2025	May 14, 2025	$-0.16	$-0.16	0.0%	= MET
Q1 2025	Mar 27, 2025	$-0.18	$-0.11	+38.9%	✓ BEAT
Q4 2024	Nov 14, 2024	$-0.23	$-0.17	+26.1%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.31	$-0.42	-35.5%	✗ MISS
Q2 2024	May 14, 2024	$-0.30	$-0.22	+26.7%	✓ BEAT
Q1 2024	Mar 26, 2024	$-0.32	$-0.29	+9.4%	✓ BEAT
Q4 2023	Nov 14, 2023	$-0.47	$-0.37	+21.3%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.33	$-0.62	-87.9%	✗ MISS
Q2 2023	May 12, 2023	$-0.40	$-0.43	-7.5%	✗ MISS
Q1 2023	Mar 23, 2023	$-0.37	$-0.39	-5.4%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.46	$-0.38	+17.4%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.35	$-0.43	-22.9%	✗ MISS
Q2 2022	May 16, 2022	$-0.34	$-0.28	+17.6%	✓ BEAT
Q1 2022	Mar 24, 2022	$-0.49	$-0.25	+49.0%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.34	$-0.39	-14.7%	✗ MISS
Q3 2021	Aug 11, 2021	$-0.31	$-0.30	+3.2%	✓ BEAT
Q2 2021	May 10, 2021	$-0.21	$-0.50	-138.1%	✗ MISS

Frequently Asked Questions about GANX

What is GANX's current stock price?

Gain Therapeutics, Inc. (GANX) is currently trading at $2.88 per share. The stock has moved +27.78% today.

What is the analyst price target for GANX?

The average analyst price target for GANX is $8.33, based on 1 analyst.

What sector is Gain Therapeutics, Inc. in?

Gain Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is GANX's market cap?

Gain Therapeutics, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.

Does GANX pay dividends?

No, Gain Therapeutics, Inc. does not currently pay a dividend to shareholders.